Evolysse
Next-generation OXIFREE hybrid HA filler technology
이 치료에 대해
Evolysse is a next-generation hyaluronic acid filler developed by Across Pharmaceuticals in Switzerland. The proprietary OXIFREE cross-linking technology minimizes oxidative reactions, providing superior stability and longevity. Delivers dynamic facial volumization while maintaining natural facial expressions and movement.
작용 기전
OXIFREE cross-linking technology significantly reduces oxidative degradation inherent in conventional cross-linking methods. The hybrid polymer network maintains elasticity post-injection while providing long-term structural stability and integration with native tissues.
적응증
기대 효과
Immediate volumization upon injection with full integration within 4-6 weeks. Results typically persist for 12-18 months. Maintains natural appearance and facial mobility throughout duration.
임상 근거
위험 및 부작용
Temporary swelling, erythema, and bruising at injection sites are common. Rare allergic reactions and granuloma formation have been documented. Intravascular injection risk is minimal with proper technique.